IPP Bureau
Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
By IPP Bureau - March 03, 2023
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC
By IPP Bureau - March 03, 2023
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
ProBioGen’s growth strategy continues successfully
By IPP Bureau - March 03, 2023
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
Vaishali Pharma bags Rs 600 crore order for antibiotics pharmaceutical products
By IPP Bureau - March 03, 2023
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
Zydus receives final approval from the USFDA for Acyclovir Cream
By IPP Bureau - March 03, 2023
he product will be launched shortly in the US market.
Department of Pharmaceuticals to celebrate 5th Jan Aushadhi Diwas on March 7
By IPP Bureau - March 01, 2023
Jan Aushadhi Diwas celebrations to generate awareness about the usages of generic medicines and benefits of Jan Aushadhi Pariyojana
5 crore health records of individuals linked to their ABHA for anytime access
By IPP Bureau - March 01, 2023
With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)
Ayush Minister inaugurates first Chintan Shivir
By IPP Bureau - March 01, 2023
Sonowal exhorted young researchers and scientist to work on evidence based scientific research
Zydus receives final approval from the USFDA for Apixaban Tablets
By IPP Bureau - March 01, 2023
Apixaban Tablets, 2.5 mg and 5 mg had annual sales of USD 18,876 mn in the United States (IQVIA MAT Dec. 2022).
Vaishali Pharma receives multiple orders worth US$ 73.85 million
By IPP Bureau - March 01, 2023
This order is subject to initial advance payment as per the agreed terms of the contract
Dr. Reddy's Laboratories to acquire Mayne Pharma’s U.S. generic prescription product portfolio
By IPP Bureau - March 01, 2023
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Zydus receives final approval from the USFDA for Hydrochlorothiazide Tablets
By IPP Bureau - March 01, 2023
This combination medicine is used to treat high blood pressure (hypertension).
AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India
By IPP Bureau - March 01, 2023
Receives regulatory approval for its molecule ‘Selumetinib’ in India
NATCO launches generic Pomalidomide Capsules in Canada
By IPP Bureau - March 01, 2023
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Alembic gets USFDA final approval for ANDA Docetaxel Injection
By IPP Bureau - March 01, 2023
